Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease

American Journal of Gastroenterology

Volumn 105, Issue 12, 2010, Pages 2610-2616

  Margolis, David J ^a   Fanelli, Matthew ^a   Hoffstad, Ole ^a   Lewis, James D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; MINOCYCLINE; OXYTETRACYCLINE;

ACNE; ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DRUG EXPOSURE; ENTERITIS; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ULCERATIVE COLITIS;

ACNE VULGARIS; CHI-SQUARE DISTRIBUTION; CONFOUNDING FACTORS (EPIDEMIOLOGY); DERMATOLOGIC AGENTS; DOXYCYCLINE; DRUG INTERACTIONS; FEMALE; GREAT BRITAIN; HUMANS; INFLAMMATORY BOWEL DISEASES; ISOTRETINOIN; MALE; MINOCYCLINE; OXYTETRACYCLINE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC; TETRACYCLINE; YOUNG ADULT;

EID: 78649856860     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.303     Document Type: Article

References (30)

1. White G M. Recent fndings in the epidemiologic evidence, classif cation, and subtypes of acne vulgaris. J Am Acad Dermatol 1998;39:S34-7.
2. Yeung C K, Teo L H, Xiang L H et al. A community-based epidemiological study of acne vulgaris in Hong Kong adolescents. Acta Derm Venereol (Stockh) 2002;82:104-7.
3. Stern R S. Teprevalence of acne on the basis of physical examination. J Am Acad Dermatol 1992;26:931-5.
4. Gollnick H, Cunlife W, B e rson D et al. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol 2004;49:S1-38.
5. Reddy D, Siegel C A, Sands B E et al. Possible association between isotretinoin and inf ammatory bowel disease. Am J Gastroenterol 2006;101:1569-73.
6. Shale M, Kaplan GG, Panaccione R et al. Isotretinoin and intestinal inflammation: what gastroenterologists need to know. Gut 2009;58:737-41.
7. Crockett SD, Porter C, Kappelman M. Isotretino in use and the risk of infammatory bowel disease: a case-control study. Am J Gastroenterol 2010;published online 30 March 2010 [e-pub ahead of print].
8. Crockett S D, Gulati A, Sandler R S et al. A causal association between isotretinoin and inf ammatory bowel disease has yet to be established. Am J Gastroenterol 2009;104:2387-93.
9. Bernstein C N, Nugent Z, Longobardi T et al. Isotretinoin is not associated with inf ammatory bowel disease: a population-based case-control study. Am J Gastroenterol 2009;104:2774-8.
10. Leyden J J. Terapy for acne vulgaris. N Engl J Med 1997;336:1156-62.
11. Card T, Logan RFA, Rodrigues LC et al. Antibiotic use and the development of Crohn's disease. Gut 2004;53:246-50.
12. Lewis JD, Schinnar R, Bilker WB et al. Validation studies of the Health Improvement Network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393-401.
13. Lewis JD, Brensinger C, Bilker W B et al. Validity and completeness of the General Practice Research Database for studies of inf ammatory bowel disease. Pharmacoepidemiol Drug Saf 2002;11:211-8.
14. Lo Re V III, Haynes K, Forde KA et al. Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf 2009;18:807-14.
15. Ruigomez A, Martin-Merino E, Rodriguez LA. Validation of ischemic cerebrovascular diagnoses in the Health Improvement Network (THIN). Pharmacoepidemiol Drug Saf 2010;19:579-85.
16. Hall GC. Validation of death and suicide recording on the THIN UK primary care database. Pharmacoepidemiol Drug Saf 2009;18:120-31.
17. Lewis JD, Brensinger C. Agreement between GPRD smoking data. PDS 2004;13:437-41.
18. Haynes K, Forde KA, Schinnar R et al. Cancer incidence in the Health Improvement Network. Pharmacoepidemiol Drug Saf 2009;18:730-6.
19. Schlienger R, Bircher AJ, Meier CR. Minocycline-induced lupus. A systematic review. Dermatology 2000;200:223-31.
20. Sturkenboom MC, Meier CR, Jick H et al. Minocycline and lupus-like syndrome in acne patients. Arch Intern Med 1999;159:493-7.
21. Margolis D, Hofstad O, Bilker W. Association or lack of association between tetracycline class antibiotics used for acne vulgaris and lupus erythematosus. Br J Dermatol 2007;157:540-6.
22. Leyden JJ. Current issues in antimicrobial therapy for the treatment of acne. J Eur Acad Dermatol Venereol 2001;15:51-5.
23. McManus P, Iheanacho I. Don't use minocycline as first line oral antibiotics in acne. BMJ 2007;334:154.
24. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006;54:258-65.
25. Velicer CM, Heckbert SR, Lampe JW et al. Antibiotic use in relation to the risk of breast cancer. JAMA 2004;291:827-35.
26. Margolis D J, Bowe W, Hofstad O et al. Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch Dermatol 2005;141:1132-6.
27. Eckburg P B, Relman D A. Terole of microbes in Crohn's disease. Clin Infect Dis 2007;44:256-62.
28. Swidsinski A, Ladhof A, Pernthaler A et al. Mucosalfora in infammatory bowel disease. Gastroenterology 2002;122:44-54.
29. Sartor R B. Microbialin fuences in infammatory bowel diseases. Gastroenterology 2008;134:577-94.
30. Bachmeyer C, Cadranel JF. Minocycline-induced lupus and autoimmune hepatitis: family autoimmune disorders as possible risk factors. Dermatology 2002;205:185-6.